SCHEMBL4197864

SCHEMBL4197864

CC(=COc1ccccc1-c1ccccc1)C(=O)OCCCOc1ccc(OCCCOC(=O)C(C)=COc2ccccc2-c2ccccc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 2/20 0.47
KDM4E B2RXH2 9/20 0.44
ALDH1A1 P00352 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TDP1 Q9NUW8 2/20 0.41
POLB P06746 1/20 0.41
APEX1 P27695 1/20 0.41
HTT P42858 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.40
PPARG P37231 1/20 0.40
PPARD Q03181 1/20 0.40
PPARA Q07869 1/20 0.40
HDAC3 O15379 4/20 0.40
HDAC4 P56524 4/20 0.40
HDAC1 Q13547 4/20 0.40
HDAC7 Q8WUI4 4/20 0.40
HDAC2 Q92769 4/20 0.40
HDAC10 Q969S8 4/20 0.40
HDAC11 Q96DB2 4/20 0.40
HDAC8 Q9BY41 4/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4197503 0.98 FFAR4 (0.48) FFAR4KDM4EALDH1A1SMN1; SMN2TDP1
SCHEMBL4186160 0.97 FFAR4 (0.47) FFAR4KDM4EALDH1A1SMN1; SMN2POLB
SCHEMBL4202057 0.93 KDM4E (0.49) KDM4EALDH1A1SMN1; SMN2POLBHTT
SCHEMBL4197813 0.92 L3MBTL1 (0.42) FFAR4KDM4EALDH1A1SMN1; SMN2TDP1
SCHEMBL4193711 0.92 KDM4E (0.51) KDM4EALDH1A1SMN1; SMN2POLBHTT
SCHEMBL4188678 0.91 FFAR4 (0.46) FFAR4KDM4EALDH1A1SMN1; SMN2POLB
SCHEMBL4198447 0.89 PPARG (0.40) FFAR4KDM4EALDH1A1SMN1; SMN2POLB
SCHEMBL4198746 0.87 FFAR4 (0.53) FFAR4KDM4EALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL4202648 0.86 FFAR4 (0.45) FFAR4KDM4EALDH1A1SMN1; SMN2TDP1
SCHEMBL4190846 0.85 KDM4E (0.40) KDM4EALDH1A1SMN1; SMN2TDP1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1627867-B1 (METH)ACRYLIC ESTER COMPOUND AND USE THEREOF MITSUI CHEMICALS INC (JP) 2016-01-20 EP disclosed
US-7534909-B2 (Meth) acrylic ester compound and use thereof MITSUI CHEMICALS, INC. (JP) 2009-05-19 US disclosed
US-20070078198-A1 (Meth) acrylic ester compound and use thereof MITSUI CHEMICALS, INC. (JP) 2007-04-05 US disclosed
EP-1627867-A1 (METH)ACRYLIC ESTER COMPOUND AND USE THEREOF Mitsui Chemicals, Inc. (JP) 2006-02-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078198-A1 (Meth) acrylic ester compound and use thereof METTL14, PAM, TAS2R41 FFAR4 1889/4885KDM4E 270/4885ALDH1A1 568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.